Introduction
Myeloid malignancies are broadly classified into acute myeloid leukemia (AML) and chronic myeloid disorders (CMDs). The latter include several 'myeloproliferative' and 'myelodysplastic' subcategories whose specific diagnosis is based primarily on bone marrow histopathology. The term 'myeloproliferative disorders' (MPDs) was first applied by William Dameshek (1900 -1969 to highlight the phenotypic similarity between chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia, and chronic idiopathic myelofibrosis (CIMF) [1] . These four disorders are now referred to as 'classic' MPDs and further sub-classified as being either BCR-ABL þ (i.e. CML) or BCR-ABL À (i.e. polycythemia vera, essential thrombocythemia, and CIMF) [2] . Such classification is now molecularly validated; an activating JAK2 mutation (JAK2V617F) is found in the majority of patients with BCR-ABL -classic MPDs [3 -6 ] whereas it is either absent or occurs infrequently in other myeloid disorders.
In addition to the classic MPDs, chronic myeloid malignancies also include the myelodysplastic syndrome (MDS) and other CMDs that are not classified as either classic MPDs or MDS. According to a recent semi-molecular classification proposal [2] , clinicopathologic entities in the latter category were grouped under the rubric of 'atypical' MPD and include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), chronic neutrophilic leukemia (CNL), chronic basophilic leukemia, hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and unclassified MPD . In contrast, the more formal WHO classification system for hematological malignancies considers four categories of CMDs: MDS, MPD, MDS/MPD, and systemic mastocytosis [7] . The WHO MPD category includes the four classic MPDs as well as CNL, CEL, HES, and unclassified MPD. The WHO MDS/MPD category includes CMML, JMML and atypical CML.
Regardless of what one chooses to use for a classification system in MPDs, a gradual transition from clinicopathologic to molecularly defined disease categorization is becoming evident (Fig. 1) . In the meantime, however, it is premature to undermine the diagnostic value of bone marrow histopathology, which, when combined with cytogenetic analysis, might also provide useful prognostic information. In the current review, we discuss how molecular tests and bone marrow histopathology are effectively combined in constructing diagnostic algorithms for each one of the three BCR-ABL -classic MPDs as well as atypical MPDs. For the purposes of the current communication, we will focus on JAK2V617F when discussing BCR-ABL -classic MPDs, but fully realize the potential role of other molecular markers that are in the process of being described, including MPLW515L/K in CIMF and essential thrombocythemia and JAK2D620E and other JAK2 mutations in polycythemia vera [8 ,9
,10].
Polycythemia vera
Because of immediate therapeutic implications, the most important objective in the evaluation of 'polycythemia' is to determine the likelihood of a polycythemia vera diagnosis. It is common knowledge that a seemingly high hematocrit level might (true polycythemia) or might not (apparent polycythemia including relative polycythemia) reflect a true increase in red cell mass [11] . Similarly, an increased red cell mass is not always associated with a hematocrit level that exceeds the 'normal' reference range (i.e. inapparent polycythemia) [12] . Therefore, the possibility of a polycythemia vera diagnosis should be entertained in the context of both an increased hematocrit level and, regardless of the hematocrit level, the presence of a polycythemia vera-characteristic clinical feature including large vein thrombosis, aquagenic pruritus, erythromelalgia, or splenomegaly. Accordingly, the best approach to the diagnosis of polycythemia vera makes use of polycythemia vera-characteristic molecular, biological, and histological disease markers that are not found in either secondary or apparent polycythemia (Fig. 2) . In this regard, the most helpful diagnostic test is mutation screening for JAK2V617F [13 ] .
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Unclassified myeloproliferative disorder (UMPD) includes both myelodysplastic syndrome (MDS)/myeloproliferative disorder (MPD) hybrids and 'atypical chronic myeloid leukemia' (CML). The far left group (CML and eosinophilia-associated MPD, MPD-eos, with PDGFR-rearrangement) are fully molecularly characterized and the pathogenetic relevance of the associated mutations have been confirmed by effective targeted therapy. In contrast, such therapeutic confirmation of pathogenetic relevance has not been demonstrated in polycythemia vera (PV), systemic mastocytosis (SM), the 8p11 myeloproliferative syndrome (EMS), despite a near-invariable association with a specific mutation. In essential thrombocythemia (ET), chronic idiopathic myelofibrosis (CIMF), myeloproliferative disorder such as ET or CIMF associated with ringed sideroblasts (MPD-RS) and juvenile myelomonocytic leukemia (JMML), recurrent mutations occur in approximately half of the patients that suggests molecular heterogeneity and the pathogenetic relevance of the associated mutations remains to be determined. Finally, there is little information regarding molecular pathogenesis for the group of diseases in the far left section of the venn diagram: UMPD, chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), chronic basophilic leukemia (CBL).
JAK2V617F is a G to T somatic mutation of JAK2, at nucleotide 1849, in exon 14, resulting in the substitution of valine to phenylalanine at codon 617. It is now becoming evident that JAK2V617F is present in nearly all patients with polycythemia vera [14] but not in other causes of polycythemia [6 , 13 ,15 ]. Therefore, screening for the particular mutation is a reasonable first line test in the evaluation of polycythemia (Fig. 2) . JAK2V617F, however, is not specific to polycythemia vera and is also found in other BCR-ABL -classic and atypical MPDs as well as MDS [3 ,4 ,5 ,6 ,15 ,16 ] . Furthermore, JAK2V617F mutation detection methods are currently not standardized and the use of either inadequately or overly sensitive assays can produce false negative [3 ] and false positive [17] results, respectively. Other confounding factors include inconsistency regarding tissue source for test samples and the occasional occurrence of JAK2V617F-negative polycythemia vera [18 ,19] . Therefore, it is advised to obtain concomitant measurement of serum erythropoietin level to overcome the aforementioned shortcomings of mutation screening (Fig. 2 ).
In the presence of JAK2V617F, diagnostic certainty for polycythemia vera, as opposed to other causes of polycythemia, is further enhanced by the demonstration of a low serum erythropoietin level; test sensitivity and specificity for the latter is above 90% and 95%, respectively [20, 21] . Therefore, when both mutation analysis and serum erythropoietin results are suggestive of polycythemia vera, bone marrow examination is not considered essential for diagnosis but is encouraged because of its value in terms of both confirmation of diagnosis and pathological staging that includes accruing baseline information on reticulin fibrosis and cytogenetic analysis ( Fig. 2) [22] . On the other hand, bone marrow examination is necessary for confirmation of diagnosis when the two test results are not in agreement. The bone marrow biopsy findings that are characteristic of polycythemia vera include hypercellularity for the patient's age that is due to trilineage proliferation ('panmyelosis') with enlarged islands of erythropoiesis and increased numbers of megakaryocytes often found in loose clusters or dispersed throughout the biopsy. The megakaryocytes are variable in size, ranging from small to large or even giant size, but lacking significant atypia in their nuclear configuration or in their and nuclear/cytoplasmic ratio [23] . Finally, the possibility of polycythemia vera, in the absence of both JAK2V617F and a low serum erythropoietin level is too low to warrant further polycythemia vera-directed investigation.
Essential thrombocythemia
Formal diagnostic criteria for essential thrombocythemia were first established in the 1970s by the Polycythemia Vera Study Group and have since been revised by the WHO-sponsored cooperative group [24] . In both instances, however, the utilization of a platelet count threshold (600 Â 10 9 /l) that is significantly higher than the upper limits of 'normal' (approximately 350 Â 10 9 /l) is not biologically sound and could lead to inadvertent oversight of phenotypically classic essential thrombocythemia cases with platelet counts between 400 and 600 Â 10 9 /l [25] [26] [27] . Regardless of this, a working diagnosis of essential thrombocythemia requires exclusion of both reactive thrombocytosis and clonal thrombocytosis associated with another myeloid disorder. Usually, patient history, physical examination, peripheral smear evaluation, and measurement of serum ferritin and C-reactive protein levels are adequate to address the possibility of reactive thrombocytosis [28] . A bone marrow examination accompanied by fluorescence in-situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL, mutation screening for JAK2V617F, and cytogenetic studies are recommended, however, for the evaluation of clinically determined, 'nonreactive' thrombocythemia in order to confirm the presence as well address the differential diagnosis of an underlying MPD (Fig. 3) .
The presence of BCR-ABL, in the context of a CMD, is diagnostic of CML [29] . In contrast, the presence of JAK2V617F, although pathognomonic of an underlying myeloid disorder, is neither essential thrombocythemia-specific (the mutation is also found in other MPDs) nor diagnostically essential (JAK2V617F is not detected in approximately half of patients with essential thrombocythemia) [30] . Therefore, at the present time, bone marrow morphological assessment remains the key diagnostic tool, in terms of both confirming an MPD diagnosis and distinguishing essential thrombocythemia from other molecularly undefined causes of clonal thrombocythemia (e.g. MDS, cellular phase CIMF) [31, 32] . In essential thrombocythemia, bone marrow findings are remarkable for the presence of large, even giant, but mature-appearing megakaryocytes with deeply lobulated nuclei that are most often dispersed throughout the biopsy sections, but sometimes also found in loose clusters [32] . Often the bone marrow is normally or only slightly hypercellular for the patient's age, and the panmyelosis that characterizes polycythemia vera and the granulocytic proliferation and highly bizarre megakaryocytes that characterize the prefibrotic stage of chronic idiopathic myelofibrosis are not found in essential thrombocythemia [33] . The presence of dyserythropoiesis, macrocytosis, monocytosis, pseudo Pelger-Huet anomaly of neutrophils or predominance of megakaryocytes with monolobated nuclei suggest MDS or atypical MPD rather than essential thrombocythemia [31] . Finally, the presence of clonal cytogenetic lesions in 'essential thrombocythemia' mandates histological and clinical reevaluation because such events are infrequent in conventionally defined essential thrombocythemia (<5%) [34] .
Chronic idiopathic myelofibrosis
The classical clinical presentation in CIMF includes marked splenomegaly and anemia although the specific diagnosis is usually suspected when one encounters the peripheral blood changes of myelophthisis or bone marrow fibrosis. Neither myelophthisis nor bone marrow fibrosis, however, is specific to CIMF and both features can also be seen in a spectrum of clonal and nonclonal conditions. In order to facilitate differential diagnosis, therefore, bone marrow biopsy should be accompanied by FISH or RT-PCR for BCR-ABL, mutation screening for JAK2V617F, and cytogenetic studies (Fig. 4) . As stated before, the presence of BCR-ABL should be considered diagnostic of CML [29] . The presence of JAK2V617F is diagnostic of an underlying clonal myeloid disorder and excludes the possibility of bone marrow fibrosis associated with infections, inflammatory processes, lymphoid disorders, or metastatic cancer [35] . The distinction between CIMF (overtly fibrotic or cellular phase), on one hand, and MDS with fibrosis, essential thrombocythemia, or acute myelofibrosis (a subtype of AML according to the WHO) [7] , on the other, however, requires careful morphological assessment [33] ; JAK2V617F is not always present in CIMF (mutational frequency is approximately 50%) and has also been described in essential thrombocythemia and in a few cases of MDS and AML [30] .
Histologically, CIMF is characterized by the presence of megakaryocytes that are morphologically more atypical than in any of the other subtypes of MPD. They are often found in sizable loose to tight clusters, and range from small to large with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous or irregularly folded nuclei. Bare megakaryocytic nuclei are common [36] . In contrast, in MDS, the classic morphologic features of myelodysplasia must be demonstrated. The dysplastic megakaryocytes in MDS tend to be small and often have monolobated, hypolobated or widely dispersed nuclei, and are not usually found in clusters as are typical for MPD. On the other hand, the presence of ringed sideroblasts, although seen regularly in MDS, may also be found in some cases of MPD, and therefore lack diagnostic specificity [37] . The distinction between cellular phase CIMF and essential thrombocythemia is often impossible from the peripheral blood alone, and therefore the degree of bone marrow cellularity observed in the biopsy (marked hypercellularity in cellular phase CIMF), presence of left-shifted and prominent granulocyte proliferation (typical in CIMF but absent in essential thrombocythemia), and megakaryocyte morphology (maturationally defective with the aforementioned nuclear features in CIMF and giant, mature-appearing megakaryocytes with well lobulated nuclei in essential thrombocythemia) [38 ] . Patients with acute myelofibrosis usually present with severe constitutional symptoms, pancytopenia, mild or no splenomegaly, and feature an increase in blood or bone marrow blast count that will often approach or fulfill the required threshold for AML diagnosis. In all cases with myelofibrosis, however, blasts may be difficult to accurately estimate and CD34 assessment by immunohistochemistry may be invaluable in such cases. Finally, although approximately half of the patients with myelofibrosis display cytogenetic abnormalities [39] , only del(13)(q12;q22) and der(6)t(1;6)(q21-23;p21-23) [40] are considered specific enough, in the context of a CMD-associated myelofibrosis, to warrant inclusion in operational diagnostic algorithms (Fig. 4) .
Atypical myeloproliferative disorders
For the purposes of this review as well as in line with a recent communication on the subject matter [2] , we will use the term 'atypical' MPDs to refer to the full spectrum of CMDs that are not classified as either classic MPDs or MDS. It should be noted that the WHO classification system incorporates these disorders into three different clinicopathologic categories: MPD (CNL, CEL, HES, unclassified MPD), MDS/MPD (CMML, JMML, atypical CML), and systemic mastocytosis [24] . Regardless of this, the role of molecular testing in atypical MPDs became most evident following the therapeutically relevant association between activating mutations of the genes for both platelet-derived growth factor receptors a (PDGFRA) and b (PDGFRB) and clonal eosinophilia [41, 42] . For example, a FIP1L1-PDGFRA fusion mutation has been demonstrated in a subset of patients that fulfill conventional diagnostic criteria for HES [41] , systemic mastocytosis [43] , or CEL [44] , whereas a PDGFRB mutation has been associated with the clinical phenotype of CEL or CMML [45] [46] [47] [48] [49] [50] . Furthermore, the presence of either one of these two mutations predicts excellent treatment response to imatinib [51] . Therefore, any atypical MPD that is associated with eosinophilia should be screened for both mutations; FIP1L1-PDGFRA is karyotypically occult and is instead detected by FISH or RT-PCR whereas the presence of PDGFRBrearrangement is suggested by conventional cytogenetic studies that show translocations involving chromosome 5q33, e.g. t(5;12)(q33;p13) [45] . Of course, CML may also present with marked eosinophilia, and exclusion of this possibility by appropriate genetic testing is also necessary.
Other eosinophilia-associated atypical MPDs (e.g. HES, molecularly undefined CEL, 8p11 myeloproliferative syndrome; Fig. 5 ) are usually imatinib-resistant. The 8p11 myeloproliferative syndrome harbors FGFR1-rearrangement and is characterized by chromosomal translocations involving chromosome 8p11, myeloproliferative and myelodysplastic features, lymphadenopathy and a high incidence of T cell non-Hodgkin's lymphoma with progression to AML [52, 53] . Molecularly undefined CEL is characterized by an 'HES' phenotype that also displays either a clonal cytogenetic abnormality or excess blasts in the bone marrow or peripheral blood [54, 55] . In contrast, a working diagnosis of HES is made only in the absence of molecular or cytogenetic markers of clonality, bone marrow mastocytosis, monocytosis, or evidence of trilineage myeloproliferation or dysplasia [56] .
Molecular markers have also been described in atypical MPDs that are not always associated with eosinophilia, including systemic mastocytosis and JMML (Fig. 5) . In FIP1L1-PDGFRA -systemic mastocytosis, nearly all adult cases might carry the KITD816V or other KIT mutations in their mast cells [57 ] . The diagnostic value of mutation screening in this instance, however, is undermined by the relatively low frequency of KIT mutation detection from either the peripheral blood or bone marrow that is not sorted for mast cells [57 ] . Therefore, at present, bone marrow morphological examination remains the primary tool for diagnosis in systemic mastocytosis; typical features include clusters of morphologically abnormal, spindle-shaped mast cells that are best evaluated by the use of immunohistochemical stains that are specific to mast cells (tryptase, CD117) [58, 59] . In addition, we recommend mast cell immunophenotyping in suspected cases in search of aberrant CD25 expression by neoplastic mast cells [60] . In JMML, which is primarily a disease of early childhood, several mutually exclusive mutations affecting one of the Ras signal transduction pathway molecules (e.g. RAS, PTPN11, NF1) have been described but their role in disease diagnosis has not been systematically studied [61] [62] [63] . Finally, at present, molecular or cytogenetic studies do not provide additional insight to histological diagnosis for the remaining group of atypical MPDs including CMML, CNL, chronic basophilic leukemia, or unclassified MPD. The latter category includes both the so-called 'MDS/ MPD histological hybrids' and 'atypical CML [64] [65] [66] [67] '.
Conclusion
At present, infallible 'gold standards' in MPD diagnostics are rare and limited to instances when a clinicopathologic entity is pathogenetically linked to a specific molecular marker such as BCR-ABL in CML. Despite this fact, many investigators continue to use consensus-based diagnostic criteria (e.g. Polycythemia Vera Study Group, WHO) as gold standards while evaluating the diagnostic accuracy of novel molecular markers. Such practice has the potential to undermine the diagnostic value of new molecular tests and one should instead utilize the information to reevaluate the status quo in diagnostic methods from the standpoint of both histopathology and consensus-based criteria. For example, do 'JAK2V617F-negative' patients with polycythemia vera represent a condition that is biologically different from 'polycythemia vera' or does it imply the presence of another mutation that is pathogenetically equivalent to JAK2V617F? Answers to such questions require careful and full utilization of bone marrow histopathology as well as longitudinal clinical assessment.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 175-176). 
